BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 16956591)

  • 1. Ebselen effects on MPTP-induced neurotoxicity.
    Dhanasekaran M; Uthayathas S; Karuppagounder SS; Parameshwaran K; Suppiramaniam V; Ebadi M; Brown-Borg HM
    Brain Res; 2006 Nov; 1118(1):251-4. PubMed ID: 16956591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D; Samantaray S; Mohanakumar KP
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease.
    Moussaoui S; Obinu MC; Daniel N; Reibaud M; Blanchard V; Imperato A
    Exp Neurol; 2000 Dec; 166(2):235-45. PubMed ID: 11085889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain.
    Oida Y; Kitaichi K; Nakayama H; Ito Y; Fujimoto Y; Shimazawa M; Nagai H; Hara H
    Brain Res; 2006 Apr; 1082(1):196-204. PubMed ID: 16515773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice.
    Sun L; Xu S; Zhou M; Wang C; Wu Y; Chan P
    Brain Res; 2010 Jun; 1335():74-82. PubMed ID: 20380823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole.
    Thomas B; Saravanan KS; Mohanakumar KP
    Neurochem Int; 2008 May; 52(6):990-1001. PubMed ID: 18164516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective aspects of a novel MAO-B inhibitor PF9601N.
    Pérez V; Morón J; Pastó M; Unzeta M
    Neurobiology (Bp); 2000; 8(3-4):231-6. PubMed ID: 11225513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
    Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
    Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.
    Wu WR; Zhu XZ; Guan HJ; Wang RG; Ji XQ
    Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):146-50. PubMed ID: 10437162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
    Kawasaki T; Ago Y; Kitao T; Nashida T; Takagi A; Takuma K; Matsuda T
    Neuropharmacology; 2008 Oct; 55(5):654-60. PubMed ID: 18573265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fucoidan protects against dopaminergic neuron death in vivo and in vitro.
    Luo D; Zhang Q; Wang H; Cui Y; Sun Z; Yang J; Zheng Y; Jia J; Yu F; Wang X; Wang X
    Eur J Pharmacol; 2009 Sep; 617(1-3):33-40. PubMed ID: 19545563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minocycline enhances MPTP toxicity to dopaminergic neurons.
    Yang L; Sugama S; Chirichigno JW; Gregorio J; Lorenzl S; Shin DH; Browne SE; Shimizu Y; Joh TH; Beal MF; Albers DS
    J Neurosci Res; 2003 Oct; 74(2):278-85. PubMed ID: 14515357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effects of ebselen are associated with the regulation of Bcl-2 and Bax proteins in cultured mouse cortical neurons.
    Xu JH; Hu HT; Liu Y; Qian YH; Liu ZH; Tan QR; Zhang ZJ
    Neurosci Lett; 2006 May; 399(3):210-4. PubMed ID: 16513270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ebselen augments its peroxidase activity by inducing nrf-2-dependent transcription.
    Tamasi V; Jeffries JM; Arteel GE; Falkner KC
    Arch Biochem Biophys; 2004 Nov; 431(2):161-8. PubMed ID: 15488464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease.
    Oyagi A; Oida Y; Hara H; Izuta H; Shimazawa M; Matsunaga N; Adachi T; Hara H
    Brain Res; 2008 Jun; 1214():169-76. PubMed ID: 18457816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ebselen attenuates cisplatin-induced ROS generation through Nrf2 activation in auditory cells.
    Kim SJ; Park C; Han AL; Youn MJ; Lee JH; Kim Y; Kim ES; Kim HJ; Kim JK; Lee HK; Chung SY; So H; Park R
    Hear Res; 2009 May; 251(1-2):70-82. PubMed ID: 19286452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
    Muñoz A; Rey P; Guerra MJ; Mendez-Alvarez E; Soto-Otero R; Labandeira-Garcia JL
    Neuropharmacology; 2006 Jul; 51(1):112-20. PubMed ID: 16678218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.